SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Ra maintains neutral outlook for pharmaceuticals sector for FY25

20 Mar 2024 Evaluate

Maintaining a neutral outlook for the pharmaceuticals sector for FY25, credit rating agency, India Ratings and Research (Ind-Ra) in its latest report is expecting pharmaceuticals companies to continue to benefit from growth in the domestic as well as export markets, while maintaining healthy EBITDA margins led by a moderation in the price erosion in the US generics business, softening of input costs, and high-value product launches in the US generic market. 

According to report named ‘FY25 Pharmaceuticals Outlook: Moving Up the Value Chain; Sustainable Margins in Sight’, the Indian pharmaceuticals market (IPM) is likely to grow 8%-9% year on year (yoy) in FY25 (FY24: 6%-7% yoy; FY23: 9.3% yoy). It further expects its US-focused pharma issuers to remain stable or report mid-to single-digit revenue growth in FY25 (FY23: 7.2% yoy; 9MFY24: 18.5% yoy) on account of lack of revenue from one-off products. Hence, the overall proportion of sales from the US is likely to remain stable. 

The report further noted that the active pharmaceuticals ingredients (API) business of Ind-Ra selected companies is expected to report high single-digit growth in FY25 due to a demand uptick. The overall revenue growth for them is also expected at around 9% yoy while maintaining healthy EBITDA margin performance (around 22%) in FY25. It also said that there has recently been a wave of M&A activity in the domestic formulations space, which is likely to continue.


About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×